Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease [Image: see text]

OBJECTIVES: Depression and antidepressant use, especially selective serotonin reuptake inhibitors (SSRIs), are common in Parkinson disease (PD). The objective of this clinical trial was to assess the efficacy of atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI), for the treatment of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A.D., Duda, J.E., Hurtig, H.I., Colcher, A., Horn, S.S., Nazem, S., Ten Have, T.R., Stern, M.B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Academy of Neurology 2010
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2918470/
https://ncbi.nlm.nih.gov/pubmed/20679638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181ebdd79
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller